Thymosin alpha-1 combined with IRX-2 (a multi-cytokine biologic) showed enhanced anti-tumor immunity in preclinical models — supporting combination immunotherapy approaches for cancer treatment.
Key findingThymosin alpha-1 combined with IRX-2 (a multi-cytokine biologic) showed enhanced anti-tumor immunity in preclinical models — supporting combination im
What the researchers found
Thymosin alpha-1 combined with IRX-2 (a multi-cytokine biologic) showed enhanced anti-tumor immunity in preclinical models — supporting combination immunotherapy approaches for cancer treatment.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.
Annals of the New York Academy of Sciences, 1194, 162-8
Citation
Naylor, Paul H; Hadden, John W. (2010). Preclinical studies with IRX-2 and thymosin alpha1 in combination therapy.. Annals of the New York Academy of Sciences, 1194, 162-8. https://doi.org/10.1111/j.1749-6632.2010.05475.x